a0265k
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of April
2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Changes
to arrangements for AGM
17 April 2020 11:00 BST
Changes to arrangements for Annual General Meeting
AstraZeneca PLC (the Company) today announced important changes to
the arrangements for the Company's forthcoming Annual General
Meeting (AGM).
The Board of Directors of the Company has been closely monitoring
the evolving COVID-19 situation. The safety and security of our
workforce and our shareholders is paramount and therefore, in
compliance with the 'Stay at Home Measures' passed into law in
England and Wales on 26 March 2020, the AGM will now take place as
a closed meeting at the Company's corporate office at Academy
House, 136 Hills Road, Cambridge, CB2 8PA on Wednesday 29 April
2020 at 14:30 BST. It will not be possible for shareholders to
attend the meeting in person.
Shareholders are strongly encouraged to appoint the Chairman of the
AGM as their proxy. This means that the Chairman of the AGM will be
able to vote on their behalf, and in accordance with their
instructions, at the AGM.
Further information, including about how shareholders may engage
with the Board, is set out in a letter to shareholders available on
the AGM section of the Company's website, at www.astrazeneca.com/agm.
AstraZeneca
AstraZeneca (LSE/STO/NYSE:
AZN)
is
a global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three therapy
areas - Oncology, Cardiovascular, Renal and Metabolism, and
Respiratory. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit
astrazeneca.com
and
follow the Company on Twitter
@AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click
here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
17 April
2020
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|